ArticleBiomaterials research2025
Prebiotic-Engineered Oral Nanoplatform against Ulcerative Colitis via Photodynamic Remodeling of Gut Microbiota and Macrophage Polarization.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoparticle-Mediated PPAR Modulation of Macrophage Polarization in Radiation Enteritis: A Narrative Review.Drug design, development and therapy · 2026Review
- Macrophage dysregulation in inflammatory bowel disease: cellular heterogeneity, pathogenic mechanism, and treatment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC), a chronic inflammatory bowel disease characterized by recurrent colonic mucosal inflammation, substantially impairs patient quality of life. While photodynamic therapy offers promise for UC treatment, conventional photosensitizers face limitations including poor solubility and inadequate targeting. Here, we developed an orally administered multifunctional nanosystem (CBF@LCP) to remodel dysbiotic gut microbiota and enable synergistic phototherapy. The core comprises reactive-oxygen-species-responsive liposomes, encapsulating our previously established iodinated cyanine photosensitizer CyI, and folic acid with bovine serum albumin via amide bonds (CBF@L). This outer layer is coated with a prebiotic chitosan/pectin shell via layer-by-layer assembly. Following oral administration, CBF@LCP withstands the gastrointestinal tract via pH-dependent contraction. Following gastrointestinal-enzyme-mediated decoating, the exposed CBF@L is internalized by folate-receptor-overexpressing M1 macrophages at colitis sites. Under near-infrared irradiation, CyI executes dual photodynamic therapy/photothermal therapy, ablating pro-inflammatory macrophages while exploiting the oxygen-augmented UC microenvironment to enhance reactive oxygen species generation without exogenous oxygen carriers. Concurrently, the prebiotic shell restores microbial eubiosis by suppressing pathogens and promoting beneficial bacteria. In vivo studies in dextran sulfate sodium-induced colitis models demonstrate that CBF@LCP achieves targeted drug release, mitigates inflammation, reprograms macrophage polarization, preserves intestinal barrier integrity, and activates the phosphatidylinositol 3-kinase/AKT signaling pathway. Gut microbiota and transcriptomic analyses confirm restoration of microbial balance and mucosal healing. This work presents a potent targeted strategy for UC management through microbiota remodeling and oxygen-enhanced phototherapy.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.